相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers
Xiaodong Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects
Tushar Garimella et al.
DRUGS IN R&D (2018)
BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications
Daiki Hira et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics
Yash Gandhi et al.
CLINICAL PHARMACOKINETICS (2018)
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys
Tsuyoshi Karibe et al.
DRUG METABOLISM AND DISPOSITION (2018)
Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin
Azusa Futatsugi et al.
DRUG METABOLISM AND DISPOSITION (2018)
Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration Between 2013 and 2016
Jingjing Yu et al.
DRUG METABOLISM AND DISPOSITION (2018)
Correlation Analysis of Potential Breast Cancer Resistance Protein Probes in Different Monolayer Systems
Zsolt Safar et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
ABCG2: does resolving its structure elucidate the mechanism?
Parth Kapoor et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2018)
Validation of a Microdose Probe Drug Cocktail for Clinical Drug Interaction Assessments for Drug Transporters and CYP3A
T. Prueksaritanont et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Dietary astaxanthin supplementation attenuates disuse-induced muscle atrophy and myonuclear apoptosis in the rat soleus muscle
Toshinori Yoshihara et al.
JOURNAL OF PHYSIOLOGICAL SCIENCES (2017)
Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
Giovanni Luca Beretta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Investigation of the Importance of Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) in the Active Efflux of Anionic Drugs Across the Blood-Brain Barrier
Kayoko Kanamitsu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
In Vitro Assessment of the Effect of Antiepileptic Drugs on Expression and Function of ABC Transporters and Their Interactions with ABCC2
Gurpreet Kaur Grewal et al.
MOLECULES (2017)
Structure of the human multidrug transporter ABCG2
Nicholas M. I. . Taylor et al.
NATURE (2017)
Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2
Noora Sjostedt et al.
PHARMACEUTICAL RESEARCH (2017)
Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro
Sabrina Nickel et al.
PHARMACEUTICAL RESEARCH (2017)
High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants
Kiyoto Tsuchiya et al.
PHARMACOGENETICS AND GENOMICS (2017)
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation
Satoshi Ueshima et al.
PHARMACOGENETICS AND GENOMICS (2017)
Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity
John T. Szilagyi et al.
PLACENTA (2017)
' The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion
Narakorn Khunweeraphong et al.
SCIENTIFIC REPORTS (2017)
Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus
Thomas Vanhove et al.
TRANSPLANTATION REVIEWS (2017)
ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches
M. C. Cleophas et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2017)
Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein
Houfu Liu et al.
DRUG METABOLISM AND DISPOSITION (2017)
Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
Q. Wang et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir
Mohamad Shebley et al.
DRUG METABOLISM AND DISPOSITION (2017)
Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin
Marta Johnson et al.
DRUG METABOLISM AND DISPOSITION (2017)
Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP
Shufan Ge et al.
PHARMACEUTICAL RESEARCH (2016)
A Review of Daclatasvir Drug-Drug Interactions
Tushar Garimella et al.
ADVANCES IN THERAPY (2016)
The C421A (Q141K) polymorphism enhances the 3′-untranslated region (3′-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2
Anne Ripperger et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin
P. Stopfer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier
M. Bauer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Membrane Transporters in Physiological Barriers of Pharmacological Importance
Ildiko Nagy et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects
J. Huguet et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants
Kiyoto Tsuchiya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans
Jeremiah D. Momper et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies
P. Martin et al.
DRUGS IN R&D (2016)
Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure
Robert Elsby et al.
DRUG METABOLISM AND DISPOSITION (2016)
Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen
Leanna Cheung et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies
Paul Martin et al.
CLINICAL THERAPEUTICS (2015)
Demethoxycurcumin Modulates Human P-Glycoprotein Function via Uncompetitive Inhibition of ATPase Hydrolysis Activity
Yu-Ning Teng et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2015)
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
Rajeev M. Menon et al.
JOURNAL OF HEPATOLOGY (2015)
Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen
Yasuo Uchida et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Bioavailability of Dietary Polyphenols and Gut Microbiota Metabolism: Antimicrobial Properties
Laura Marin et al.
BIOMED RESEARCH INTERNATIONAL (2015)
A new ABCG2 null allele with a 27-kb deletion including the promoter region causing the Jr(a-) phenotype
Kenichi Ogasawara et al.
TRANSFUSION (2015)
Effect of Lapatinib on Oral Digoxin Absorption in Patients
Kevin M. Koch et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)
Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design
Caroline A. Lee et al.
DRUG METABOLISM AND DISPOSITION (2015)
Zinc Finger Nuclease-Mediated Gene Knockout Results in Loss of Transport Activity for P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells
Kathleen E. Sampson et al.
DRUG METABOLISM AND DISPOSITION (2015)
Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides
Tomomi Furihata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics
Marton Jani et al.
ARCHIVES OF TOXICOLOGY (2014)
Expression of membrane transporters and metabolic enzymes involved in estrone-3-sulphate disposition in human breast tumour tissues
Nilasha Banerjee et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
The role of the efflux carriers Abcg2 and Abcc2 for the hepatobiliary elimination of benzo[a]pyrene and its metabolites in mice
Jasmin Kranz et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2014)
The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus
Timothy Eley et al.
CLINICAL DRUG INVESTIGATION (2014)
Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants
Kiyoto Tsuchiya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line
Karin Skoglund et al.
PHARMACOGENETICS AND GENOMICS (2014)
Renal glucuronidation and multidrug resistance protein 2-/multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus
Azza A. K. El-Sheikh et al.
TRANSLATIONAL RESEARCH (2014)
ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib
Douglas Vivona et al.
ONCOLOGY LETTERS (2014)
Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo
Agnes Poirier et al.
DRUG METABOLISM AND DISPOSITION (2014)
The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug Discovery and Development: Why, When, and How?
Agnse Poirier et al.
DRUG METABOLISM AND DISPOSITION (2014)
Interaction of Novel Platelet-Increasing Agent Eltrombopag with Rosuvastatin via Breast Cancer Resistance Protein in Humans
Kazuya Takeuchi et al.
DRUG METABOLISM AND DISPOSITION (2014)
Mass Spectrometry-Based Targeted Proteomics as a Tool to Elucidate the Expression and Function of Intestinal Drug Transporters
Stefan Oswald et al.
AAPS JOURNAL (2013)
Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry
Inna Y. Gong et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2013)
Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein
Hajnalka Saranko et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+T-cells as an interaction target for anti-HIV agents
Yumi Hashiguchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
Wolfgang Mueck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A P-gp vesicular transport inhibition assay - Optimization and validation for drug-drug interaction testing
Krisztina Heredi-Szabo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
The interaction between human breast cancer resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids
Ye Tian et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): Effect of age, sex, and genotype
Bhagwat Prasad et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Synthesis and ABCG2 Inhibitory Activity of Novel Fumitremorgin C Analogs - Specificity and Structure Activity Correlations
Orsolya Szolomajer-Csikos et al.
MEDICINAL CHEMISTRY (2013)
ABCB1 single nucleotide polymorphisms (1236C > T, 2677G > T, and 3435C > T) do not affect transport activity of human P-glycoprotein
David Dickens et al.
PHARMACOGENETICS AND GENOMICS (2013)
In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor
Melinda J. Reese et al.
DRUG METABOLISM AND DISPOSITION (2013)
Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes
Nathan D. Pfeifer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria
Joe Bentz et al.
DRUG METABOLISM AND DISPOSITION (2013)
Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Biliary Excretion of Curcumin Is Mediated by Multidrug Resistance-Associated Protein 2
Joo Hyun Lee et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2012)
Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP
Hiroyuki Kusuhara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter
Agnes Basseville et al.
CANCER RESEARCH (2012)
Understanding the Critical Disposition Pathways of Statins to Assess Drug-Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
R. Elsby et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
ABCG2 Modulates Chlorothiazide Permeability In Vitro-characterization of Its Interactions
Erzsebet Beery et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
Tomoyuki Mizuno et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Differential Selectivity of Efflux Transporter Inhibitors in Caco-2 and MDCK-MDR1 Monolayers: A Strategy to Assess the Interaction of a New Chemical Entity with P-gp, BCRP, and MRP2
Kirsten Mease et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
ABCG2 null alleles define the Jr(a-) blood group phenotype
Teresa Zelinski et al.
NATURE GENETICS (2012)
Deletion of Abcg2 Has Differential Effects on Excretion and Pharmacokinetics of Probe Substrates in Rats
Liyue Huang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics
Maciej J. Zamek-Gliszczynski et al.
DRUG METABOLISM AND DISPOSITION (2012)
Breast Cancer Resistance Protein (ABCG2) Determines Distribution of Genistein Phase II Metabolites: Reevaluation of the Roles of ABCG2 in the Disposition of Genistein
Zhen Yang et al.
DRUG METABOLISM AND DISPOSITION (2012)
Cerebrospinal Fluid Can Be Used as a Surrogate to Assess Brain Exposures of Breast Cancer Resistance Protein and P-Glycoprotein Substrates
Guangqing Xiao et al.
DRUG METABOLISM AND DISPOSITION (2012)
Identification of Proline Residues in or near the Transmembrane Helices of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) That Are Important for Transport Activity and Substrate Specificity
Zhanglin Ni et al.
BIOCHEMISTRY (2011)
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers
Alicia J. Allred et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model
Xuena Lin et al.
DRUG METABOLISM AND DISPOSITION (2011)
Bioavailability of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein in Breast Cancer Resistance Protein 1 Knockout Mice
Ana I. Alvarez et al.
DRUG METABOLISM AND DISPOSITION (2011)
Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
Robert Elsby et al.
XENOBIOTICA (2011)
Intestinal absorbability of three Radix Puerariae isoflavones including daidzein, daidzin and puerarin
Li Zhang et al.
CHINESE MEDICINE (2011)
Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs
Jibin Li et al.
DRUG METABOLISM AND DISPOSITION (2011)
Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport
Zhanglin Ni et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2010)
von Willebrand factor self-association on platelet GpIbα under hydrodynamic shear: effect on shear-induced platelet activation
Kannayakanahalli M. Dayananda et al.
BLOOD (2010)
ABCG2 Transports and Transfers Heme to Albumin through Its Large Extracellular Loop
Elodie Desuzinges-Mandon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration
Kimberly K. Adkison et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2)
Shiyan Guo et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2010)
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting
Arik Dahan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Kinetic Characterization of Sulfasalazine Transport by Human ATP-Binding Cassette G2
Marton Jani et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A
Sandrine Turpault et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Compartment-Specific Roles of ATP-Binding Cassette Transporters Define Differential Topotecan Distribution in Brain Parenchyma and Cerebrospinal Fluid
Jun Shen et al.
CANCER RESEARCH (2009)
Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo
Maria L. H. Vlaming et al.
CLINICAL CANCER RESEARCH (2009)
Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design
Nagdeep Giri et al.
DRUG METABOLISM AND DISPOSITION (2009)
The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice
Lin Zhou et al.
DRUG METABOLISM AND DISPOSITION (2009)
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
Takao Watanabe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Intestinal Breast Cancer Resistance Protein (BCRP)/Bcrp1 and Multidrug Resistance Protein 3 (MRP3)/Mrp3 Are Involved in the Pharmacokinetics of Resveratrol
Koen van de Wetering et al.
MOLECULAR PHARMACOLOGY (2009)
Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs
Par Matsson et al.
PHARMACEUTICAL RESEARCH (2009)
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans
Y. Yamasaki et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds
Junichi Enokizono et al.
DRUG METABOLISM AND DISPOSITION (2008)
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin
Satoshi Kitamura et al.
DRUG METABOLISM AND DISPOSITION (2008)
Utilization of membrane vesicle preparations to study drug-ABC transporter interactions
Hristos Glavinas et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Application and limitation of inhibitors in drug-transporter interactions studies
Qing Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Homology modeling of breast cancer resistance protein (ABCG2)
Eszter Hazai et al.
JOURNAL OF STRUCTURAL BIOLOGY (2008)
Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells
Hong Li et al.
PHARMACEUTICAL RESEARCH (2008)
Breast cancer resistance protein (ABCG2) and drug disposition:: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe
Bradley L. Urquhart et al.
PHARMACOGENETICS AND GENOMICS (2008)
ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta
Paivi Myllynen et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2008)
The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) disposition and drug interactions
Joseph W. Polli et al.
DRUG METABOLISM AND DISPOSITION (2008)
Characterization of 5(6)-carboxy-2,′7′-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4
Krisztina Heredi-Szabo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2008)
Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones
Tomohiro Ando et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens
Junichi Enokizono et al.
MOLECULAR PHARMACOLOGY (2007)
Cholesterol potentiates ABCG2 activity in a heterologous expression system:: Improved in vitro model to study function of human ABCG2
A. Pal et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk
Antonius E. van Herwaarden et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2
Ai Tamura et al.
CANCER SCIENCE (2007)
Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta
Markus Grube et al.
DRUG METABOLISM AND DISPOSITION (2007)
An in vitro and in silico study on the flavonold-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers
Maaike E. Schutte et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein
JP Keogh et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse
Hani Zaher et al.
MOLECULAR PHARMACEUTICS (2006)
Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk
AE van Herwaarden et al.
CARCINOGENESIS (2006)
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion- transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein
S Matsushima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells
CQ Xia et al.
DRUG METABOLISM AND DISPOSITION (2005)
Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2
K Letschert et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk
JW Jonker et al.
NATURE MEDICINE (2005)
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine
SG Simonson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins
SE Bates et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Mutational analysis of ABCG2: Role of the GXXXG motif
O Polgar et al.
BIOCHEMISTRY (2004)
The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme
P Krishnamurthy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The human fetal adrenal: Making adrenal androgens for placental estrogens
WE Rainey et al.
SEMINARS IN REPRODUCTIVE MEDICINE (2004)
Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2
JK Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Functional analysis of SNPs variants of BCRP/ABCG2
C Kondo et al.
PHARMACEUTICAL RESEARCH (2004)
Breast cancer resistance protein exports sulfated estrogens but not free estrogens
Y Imai et al.
MOLECULAR PHARMACOLOGY (2003)
Interplay between MRP inhibition and metabolism of MRP inhibitors: The case of curcumin
HM Wortelboer et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2003)
Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter -: Modulation of substrate specificity by a point mutation
C Özvegy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
JW Jonker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats
CG Dietrich et al.
MOLECULAR PHARMACOLOGY (2001)
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines
A van Loevezijn et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Inhibitory effect of the reversal agents V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport
R Evers et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
